Empresa Oxygen Biotherapeutics, Inc. Nasdaq
Acciones
US69207P2092
Biotecnología e investigación médica
Precio de cierre
Otros sitios de cotización
|
||
- USD | - |
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 50 | 14/07/21 | |
Director of Finance/CFO | 69 | 11/01 | |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15/01/21 |
Doug Randall
COO | Chief Operating Officer | - | 14/11/13 |
Douglas Hay
LAW | General Counsel | - | 14/11/13 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Gerry Proehl
CHM | Chairman | 65 | 04/04/14 |
June Almenoff
BRD | Director/Board Member | 67 | 25/02/21 |
Declan Doogan
BRD | Director/Board Member | 72 | 25/02/21 |
Michael Davidson
BRD | Director/Board Member | 67 | 25/02/21 |
Robyn Hunter
BRD | Director/Board Member | 62 | 28/01/22 |
Stuart Rich
CTO | Chief Tech/Sci/R&D Officer | 74 | 15/01/21 |
Chief Executive Officer | 50 | 14/07/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 210 | 0 | 0 | 99,65 % |
Acción B | 1 | 1 958 245 | 1 951 297 ( 99,65 %) | 0 |
Información de la empresa
Tenax Therapeutics, Inc.
101 Glen Lennox Drive Suite 300
27517, Chapel Hill
+(919) 855-2100
http://www.tenaxthera.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+23,13 % | 52,73 mil M | |
+37,49 % | 39 mil M | |
-8,73 % | 38,52 mil M | |
+28,09 % | 30,38 mil M | |
-12,26 % | 26,39 mil M | |
+10,57 % | 26,08 mil M | |
+45,05 % | 14,15 mil M | |
+32,23 % | 12,6 mil M | |
-6,56 % | 11,51 mil M |
- Bolsa de valores
- Acciones
- Acción TENX
- Acción
- Empresa Oxygen Biotherapeutics, Inc.